Title: Role of Efonidipine in CKD Patients: A Study In North Bihar
Authors: Dr U. C. Jha, Dr Ashish Narayan
The role of efonidipine, a calcium channel blocker in reducing the progression of chronic renal disease is well established by various studies. It also imparts beneficial effects in cardiovascular disease by reducing synthesis and secretion of aldosterone, it prevents hypertrophy and remodelling of cardiac myocytes. There is decrease in 24 hour urinary protein as efonidipine reduces glomerular capillary pressure. And overall there is improvement in GFR too. The aim of the study is to find the role of efonidipine in CKD patients.
Methods: CKD patients (age >25 years, both gender) attending outdoor clinic and indoor CKD patients of Medicine department Darbhanga Medical College were selected by simple random method and advised efonidipine 40mg once daily. The statistical significance of improvement in proteinuria and GFR was measured.
Result: There was improvement in proteinuria in 52% patients taking efonidipine 40mg once daily. The GFR was increased in 54% patients taking drug.
Out of 50 patients 29 were male and 21 were females. There was substantial decrease in 24 hour urinary protein in 26 patients out of 50 at the end of 6 months period. GFR also improved in 27 patients out of 50 at the end of study period.
Conclusion: Our 24 weeks study period in CKD patients taking efonidipine a novel dihydropyridine calcium antagonist showed its beneficial effects. The outcome was measured by 24 hour urinary protein excretion and GFR. The beneficial effect on proteinuria was particularly apparent in patients with proteinuria 1 g/day. These effects of efonidipine would appear to make the drug more advantageous than other CCBs in terms of slowing the progression of renal dysfunction and preventing cardiovascular tissue and organ injuries in patients with hypertension and chronic kidney disease.